Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
- PMID: 9351374
- DOI: 10.1161/01.atv.17.10.2074
Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells
Abstract
An increased plasma homocysteine level is an independent risk factor for vascular disease. However, the pathological mechanisms by which homocysteine promotes atherosclerosis are not yet clearly defined. Arterial smooth muscle cells cultured in the presence of homocysteine grew to a higher density and produced and accumulated collagen at levels significantly above control values. Homocysteine concentrations as low as 50 mumol/L significantly increased both cell density and collagen production. Cell density increased by as much as 43% in homocysteine-treated cultures. Homocysteine increased collagen production in a dose-dependent manner. Smooth muscle cells treated with homocysteine at concentrations observed in patients with hyperhomocysteinemia had collagen synthesis rates as high as 214% of control values. Likewise, collagen accumulation in the cell layer was nearly doubled in homocysteine-treated cultures. Addition of aquacobalamin to homocysteine-treated cultures controlled the increase in smooth muscle cell proliferation and collagen production. These results indicate a cellular mechanism for the atherogenicity of homocysteine and provide insight into a potential preventive treatment.
Similar articles
-
Molecular mechanisms of cholesterol or homocysteine effect in the development of atherosclerosis: Role of vitamin E.Biofactors. 2003;19(1-2):63-70. doi: 10.1002/biof.5520190108. Biofactors. 2003. PMID: 14757978
-
Upregulation of smooth muscle cell collagen production by homocysteine-insight into the pathogenesis of homocystinuria.Mol Genet Metab. 2002 Jun;76(2):92-9. doi: 10.1016/s1096-7192(02)00030-6. Mol Genet Metab. 2002. PMID: 12083806
-
Homocysteine and the production of collagens, proliferation and apoptosis in human arterial smooth muscle cells.APMIS. 2004 Sep;112(9):598-604. doi: 10.1111/j.1600-0463.2004.apm1120907.x. APMIS. 2004. PMID: 15601309
-
Pathogenesis of vascular disease in hyperhomocysteinaemia.J Cardiovasc Risk. 1998 Aug;5(4):239-47. J Cardiovasc Risk. 1998. PMID: 9919472 Review.
-
Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease.J Assoc Physicians India. 2002 May;50 Suppl:16-23. J Assoc Physicians India. 2002. PMID: 12186151 Review.
Cited by
-
Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting.J Atheroscler Thromb. 2017 Jul 1;24(7):696-705. doi: 10.5551/jat.36434. Epub 2016 Nov 1. J Atheroscler Thromb. 2017. PMID: 27803490 Free PMC article. Clinical Trial.
-
Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis.Inflammation. 2001 Jun;25(3):179-86. doi: 10.1023/a:1011088431191. Inflammation. 2001. PMID: 11403209
-
Linagliptin and secoisolariciresinol diglucoside attenuate hyperlipidemia and cardiac hypertrophy induced by a high-methionine diet in rats via suppression of hyperhomocysteinemia-induced endoplasmic reticulum stress.Front Pharmacol. 2023 Nov 9;14:1275730. doi: 10.3389/fphar.2023.1275730. eCollection 2023. Front Pharmacol. 2023. PMID: 38026992 Free PMC article.
-
Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis.Apoptosis. 2007 Aug;12(8):1407-18. doi: 10.1007/s10495-007-0077-5. Apoptosis. 2007. PMID: 17440815 Free PMC article.
-
Clinical relevance of hyperhomocysteinaemia in atherothrombotic disease.Drugs Aging. 2000 Apr;16(4):251-60. doi: 10.2165/00002512-200016040-00001. Drugs Aging. 2000. PMID: 10874520 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources